↓ Skip to main content

PDGFA/PDGFRα-regulated GOLM1 promotes human glioma progression through activation of AKT

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, December 2017
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
PDGFA/PDGFRα-regulated GOLM1 promotes human glioma progression through activation of AKT
Published in
Journal of Experimental & Clinical Cancer Research, December 2017
DOI 10.1186/s13046-017-0665-3
Pubmed ID
Authors

Ran Xu, Jianxiong Ji, Xin Zhang, Mingzhi Han, Chao Zhang, Yangyang Xu, Yuzhen Wei, Shuai Wang, Bin Huang, Anjing Chen, Di Zhang, Qing Zhang, Wenjie Li, Zheng Jiang, Jian Wang, Xingang Li

Abstract

Golgi Membrane Protein 1 (GOLM1), a protein involved in the trafficking of proteins through the Golgi apparatus, has been shown to be oncogenic in a variety of human cancers. Here, we examined the role of GOLM1 in the development of human glioma. qRT-PCR, immunohistochemistry, and western blot analysis were performed to evaluate GOLM1 levels in cell lines and a cohort of primary human glioma and non-neoplastic brain tissue samples. Glioma cell lines were modified with lentiviral constructs expressing short hairpin RNAs targeting GOLM1 or overexpressing the protein to assess function in proliferation, viability, and migration and invasion in vitro using EdU, CCK8, clone-forming, Transwell assays, 3D tumor spheroid invasion assay and in vivo in orthotopic implantations. Protein lysates were used to screen a membrane-based antibody array to identify kinases mediated by GOLM1. Specific inhibitors of PDGFRα (AG1296) and AKT (MK-2206) were used to examine the regulation of PDGFA/PDGFRα on GOLM1 and the underlying pathway respectively. qRT-PCR, immunohistochemistry and western blot analysis revealed GOLM1 expression to be elevated in glioma tissues and cell lines. Silencing of GOLM1 attenuated proliferation, migration, and invasion of U251, A172 and P3#GBM (primary glioma) cells, while overexpression of GOLM1 enhanced malignant behavior of U87MG cells. We further demonstrated that activation of AKT is the driving force of GOLM1-promoted glioma progression. The last finding of this research belongs to the regulation of PDGFA/PDGFRα on GOLM1, while GOLM1 was also a key element of PDGFA/PDGFRα-mediated activation of AKT, as well as the progression of glioma cells. PDGFA/PDGFRα-regulated GOLM1 promotes glioma progression possibly through activation of a key signaling kinase, AKT. GOLM1 interference may therefore provide a novel therapeutic target and improve the efficacy of glioma treatment, particularly in the case of the proneural molecular subtype of human glioma.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 21%
Student > Ph. D. Student 5 18%
Student > Bachelor 3 11%
Student > Postgraduate 2 7%
Student > Master 2 7%
Other 3 11%
Unknown 7 25%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 18%
Medicine and Dentistry 5 18%
Agricultural and Biological Sciences 3 11%
Neuroscience 3 11%
Immunology and Microbiology 2 7%
Other 2 7%
Unknown 8 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 December 2017.
All research outputs
#22,764,772
of 25,382,440 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#1,969
of 2,380 outputs
Outputs of similar age
#388,599
of 448,935 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#33
of 44 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,380 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,935 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.